Home > Research > Publications & Outputs > High residual carriage of vaccine-serotype Stre...

Links

Text available via DOI:

View graph of relations

High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. / Swarthout, T.D.; Fronterre, C.; Lourenço, J. et al.
In: Nature Communications, Vol. 11, No. 1, 2222, 06.05.2020.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Swarthout, TD, Fronterre, C, Lourenço, J, Obolski, U, Gori, A, Bar-Zeev, N, Everett, D, Kamng'ona, AW, Mwalukomo, TS, Mataya, AA, Mwansambo, C, Banda, M, Gupta, S, Diggle, P, French, N & Heyderman, RS 2020, 'High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi', Nature Communications, vol. 11, no. 1, 2222. https://doi.org/10.1038/s41467-020-15786-9

APA

Swarthout, T. D., Fronterre, C., Lourenço, J., Obolski, U., Gori, A., Bar-Zeev, N., Everett, D., Kamng'ona, A. W., Mwalukomo, T. S., Mataya, A. A., Mwansambo, C., Banda, M., Gupta, S., Diggle, P., French, N., & Heyderman, R. S. (2020). High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nature Communications, 11(1), Article 2222. https://doi.org/10.1038/s41467-020-15786-9

Vancouver

Swarthout TD, Fronterre C, Lourenço J, Obolski U, Gori A, Bar-Zeev N et al. High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi. Nature Communications. 2020 May 6;11(1):2222. doi: 10.1038/s41467-020-15786-9

Author

Bibtex

@article{557451e27f6c49b3b8905280cbb242be,
title = "High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi",
abstract = "There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Africa sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and transmission. Here we assess PCV carriage using rolling, prospective nasopharyngeal carriage surveys between 2015 and 2018, 3.6–7.1 years after Malawi{\textquoteright}s 2011 PCV13 introduction. Carriage decay rate is analysed using non-linear regression. Despite evidence of reduction in VT carriage over the study period, there is high persistent residual carriage. This includes among PCV-vaccinated children 3–5-year-old (16.1% relative reduction from 19.9% to 16.7%); PCV-unvaccinated children 6–8-year-old (40.5% reduction from 26.4% to 15.7%); HIV-infected adults 18-40-years-old on antiretroviral therapy (41.4% reduction from 15.2% to 8.9%). VT carriage prevalence half-life is similar among PCV-vaccinated and PCV-unvaccinated children (3.26 and 3.34 years, respectively). Compared with high-income settings, there is high residual VT carriage 3.6–7.1 years after PCV introduction. Rigorous evaluation of strategies to augment vaccine-induced control of carriage, including alternative schedules and catch-up campaigns, is required.",
author = "T.D. Swarthout and C. Fronterre and J. Louren{\c c}o and U. Obolski and A. Gori and N. Bar-Zeev and D. Everett and A.W. Kamng'ona and T.S. Mwalukomo and A.A. Mataya and C. Mwansambo and M. Banda and S. Gupta and P. Diggle and N. French and R.S. Heyderman",
year = "2020",
month = may,
day = "6",
doi = "10.1038/s41467-020-15786-9",
language = "English",
volume = "11",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi

AU - Swarthout, T.D.

AU - Fronterre, C.

AU - Lourenço, J.

AU - Obolski, U.

AU - Gori, A.

AU - Bar-Zeev, N.

AU - Everett, D.

AU - Kamng'ona, A.W.

AU - Mwalukomo, T.S.

AU - Mataya, A.A.

AU - Mwansambo, C.

AU - Banda, M.

AU - Gupta, S.

AU - Diggle, P.

AU - French, N.

AU - Heyderman, R.S.

PY - 2020/5/6

Y1 - 2020/5/6

N2 - There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Africa sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and transmission. Here we assess PCV carriage using rolling, prospective nasopharyngeal carriage surveys between 2015 and 2018, 3.6–7.1 years after Malawi’s 2011 PCV13 introduction. Carriage decay rate is analysed using non-linear regression. Despite evidence of reduction in VT carriage over the study period, there is high persistent residual carriage. This includes among PCV-vaccinated children 3–5-year-old (16.1% relative reduction from 19.9% to 16.7%); PCV-unvaccinated children 6–8-year-old (40.5% reduction from 26.4% to 15.7%); HIV-infected adults 18-40-years-old on antiretroviral therapy (41.4% reduction from 15.2% to 8.9%). VT carriage prevalence half-life is similar among PCV-vaccinated and PCV-unvaccinated children (3.26 and 3.34 years, respectively). Compared with high-income settings, there is high residual VT carriage 3.6–7.1 years after PCV introduction. Rigorous evaluation of strategies to augment vaccine-induced control of carriage, including alternative schedules and catch-up campaigns, is required.

AB - There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Africa sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and transmission. Here we assess PCV carriage using rolling, prospective nasopharyngeal carriage surveys between 2015 and 2018, 3.6–7.1 years after Malawi’s 2011 PCV13 introduction. Carriage decay rate is analysed using non-linear regression. Despite evidence of reduction in VT carriage over the study period, there is high persistent residual carriage. This includes among PCV-vaccinated children 3–5-year-old (16.1% relative reduction from 19.9% to 16.7%); PCV-unvaccinated children 6–8-year-old (40.5% reduction from 26.4% to 15.7%); HIV-infected adults 18-40-years-old on antiretroviral therapy (41.4% reduction from 15.2% to 8.9%). VT carriage prevalence half-life is similar among PCV-vaccinated and PCV-unvaccinated children (3.26 and 3.34 years, respectively). Compared with high-income settings, there is high residual VT carriage 3.6–7.1 years after PCV introduction. Rigorous evaluation of strategies to augment vaccine-induced control of carriage, including alternative schedules and catch-up campaigns, is required.

U2 - 10.1038/s41467-020-15786-9

DO - 10.1038/s41467-020-15786-9

M3 - Journal article

VL - 11

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 2222

ER -